Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR known ✓ | P30968 | 20/20 | 0.73 |
| ▸ | KCNH2 known ✓ | Q12809 | 10/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30174366 | 1.00 | GNRHR (0.73) | GNRHRKCNH2 | |
| SCHEMBL17092964 | 0.99 | GNRHR (0.74) | GNRHRKCNH2 | |
| SCHEMBL29605045 | 0.99 | GNRHR (0.74) | GNRHRKCNH2 | |
| Hydrochloric Acid SCHEMBL31418380 | 0.93 | GNRHR (0.63) | GNRHRKCNH2 | |
| SCHEMBL30461687 | 0.92 | GNRHR (0.73) | GNRHRKCNH2 | |
| SCHEMBL30461571 | 0.92 | GNRHR (0.69) | GNRHRKCNH2 | |
| SCHEMBL30461575 | 0.91 | GNRHR (0.68) | GNRHRKCNH2 | |
| SCHEMBL28490029 | 0.91 | GNRHR (0.68) | GNRHRKCNH2 | |
| SCHEMBL29966967 | 0.90 | GNRHR (0.76) | GNRHRKCNH2 | |
| SCHEMBL29385627 | 0.90 | GNRHR (0.61) | GNRHRKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12325714-B2 | Compositions of thienopyrimidine derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-06-10 | — | — | US | disclosed |
| US-20250051353-A1 | COMPOSITIONS OF THIENOPYRIMIDINE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-02-13 | — | — | US | disclosed |
| US-12180224-B2 | Thienopyrimidine derivatives and production methods thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-12-31 | — | — | US | disclosed |
| US-11795178-B2 | Compositions of thienopyrimidine derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-24 | — | — | US | disclosed |
| US-11731983-B2 | Production method of thienopyrimidine derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-08-22 | — | — | US | disclosed |
| US-20230212184-A1 | THIENOPYRIMIDINE DERIVATIVES AND PRODUCTION METHODS THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-07-06 | — | — | US | disclosed |
| EP-4119564-A1 | PRODUCTION METHOD OF THIENOPYRIMIDINE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2023-01-18 | — | — | EP | disclosed |
| US-20220204525-A1 | COMPOSITIONS OF THIENOPYRIMIDINE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-06-30 | — | — | US | disclosed |
| US-20220135585-A1 | PRODUCTION METHOD OF THIENOPYRIMIDINE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-05-05 | — | — | US | disclosed |
| EP-3415517-B1 | CRYSTALLINE FORM OF 1-(4-1-(2,6-DIFLUOROBENZYL)-5-DIMETHYLAMINOMETHYL-3-(6-METHOXYPYRIDAZIN-3-YL)-2,4-DIOXO-1,2,3,4-TETRAHYDROTHIENO(2,3-D)-PYRIMIDIN-6YL)PHENYL)-3-METHOXYUREA | TAKEDA PHARMACEUTICALS CO (JP) | 2022-04-20 | — | — | EP | disclosed |
| US-20200361953-A1 | PRODUCTION METHOD OF THIENOPYRIMIDINE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-11-19 | — | — | US | disclosed |
| US-10544160-B2 | Production method of thienopyrimidine derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-01-28 | — | — | US | disclosed |
| US-10464945-B2 | Crystalline forms of thienopyrimidine derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-11-05 | — | — | US | disclosed |
| US-20190055261-A1 | PRODUCTION METHOD OF THIENOPYRIMIDINE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-02-21 | — | — | US | disclosed |
| EP-3415517-A1 | CRYSTALLINE FORM OF 1-(4-1-(2,6-DIFLUOROBENZYL)-5-DIMETHYLAMINOMETHYL-3-(6-METHOXYPYRIDAZIN-3-YL)-2,4-DIOXO-1,2,3,4-TETRAHYDROTHIENO(2,3-D)-PYRIMIDIN-6YL)PHENYL)-3-METHOXYUREA | Takeda Pharmaceutical Company Limited (JP) | 2018-12-19 | — | — | EP | disclosed |
| US-10150778-B2 | Production method of thienopyrimidine derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-12-11 | — | — | US | disclosed |
| US-20180319816-A1 | PRODUCTION METHOD OF THIENOPYRIMIDINE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-11-08 | — | — | US | disclosed |
| US-9758528-B2 | Production method of thienopyrimidine derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-12 | — | — | US | disclosed |
| US-20170210753-A1 | PRODUCTION METHOD OF THIENOPYRIMIDINE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-07-27 | — | — | US | disclosed |
| US-20150266891-A1 | PRODUCTION METHOD OF THIENOPYRIMIDINE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795178-B2 | Compositions of thienopyrimidine derivatives | GNRHR, KISS1R, MC4R | GNRHR 1/4885KCNH2 962/4885 |
| US-20190055261-A1 | PRODUCTION METHOD OF THIENOPYRIMIDINE DERIVATIVE | GNRHR, KISS1R, NR5A1 | GNRHR 1/4885KCNH2 1265/4885 |
| US-10464945-B2 | Crystalline forms of thienopyrimidine derivative | GNRHR, NR5A1, KISS1R | GNRHR 1/4885KCNH2 1285/4885 |
| US-20200361953-A1 | PRODUCTION METHOD OF THIENOPYRIMIDINE DERIVATIVE | GNRHR, KISS1R, NR5A1 | GNRHR 1/4885KCNH2 1356/4885 |
| US-20250051353-A1 | COMPOSITIONS OF THIENOPYRIMIDINE DERIVATIVES | GNRHR, KISS1R, NR5A1 | GNRHR 1/4885KCNH2 1167/4885 |
| US-20220135585-A1 | PRODUCTION METHOD OF THIENOPYRIMIDINE DERIVATIVE | GNRHR, KISS1R, NR5A1 | GNRHR 1/4885KCNH2 1265/4885 |
| US-20150266891-A1 | PRODUCTION METHOD OF THIENOPYRIMIDINE DERIVATIVE | GNRHR, KISS1R, NR5A1 | GNRHR 1/4885KCNH2 1246/4885 |
| US-20220204525-A1 | COMPOSITIONS OF THIENOPYRIMIDINE DERIVATIVES | GNRHR, KISS1R, MC4R | GNRHR 1/4885KCNH2 962/4885 |
| US-12180224-B2 | Thienopyrimidine derivatives and production methods thereof | GNRHR, KISS1R, MC4R | GNRHR 1/4885KCNH2 1017/4885 |
| US-10544160-B2 | Production method of thienopyrimidine derivative | GNRHR, KISS1R, NR5A1 | GNRHR 1/4885KCNH2 1265/4885 |
| US-10150778-B2 | Production method of thienopyrimidine derivative | GNRHR, KISS1R, NR5A1 | GNRHR 1/4885KCNH2 1265/4885 |
| US-20230212184-A1 | THIENOPYRIMIDINE DERIVATIVES AND PRODUCTION METHODS THEREOF | GNRHR, KISS1R, MC4R | GNRHR 1/4885KCNH2 1017/4885 |
| US-11731983-B2 | Production method of thienopyrimidine derivative | GNRHR, KISS1R, NR5A1 | GNRHR 1/4885KCNH2 1265/4885 |
| US-20170210753-A1 | PRODUCTION METHOD OF THIENOPYRIMIDINE DERIVATIVE | GNRHR, KISS1R, NR5A1 | GNRHR 1/4885KCNH2 1265/4885 |
| US-20180319816-A1 | PRODUCTION METHOD OF THIENOPYRIMIDINE DERIVATIVE | GNRHR, KISS1R, NR5A1 | GNRHR 1/4885KCNH2 1265/4885 |
| US-12325714-B2 | Compositions of thienopyrimidine derivatives | GNRHR, KISS1R, NR5A1 | GNRHR 1/4885KCNH2 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.